GlassScriptPhysician profile
Nathan S Overbey
NPI 1457795247
$5,327.68
in general payments reported to CMS, 2019-2025
33 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $781 · 2021: $323 · 2022: $1,712 · 2023: $476 · 2024: $404 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,817.95 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Medtronic USA, INC. | $831.90 | 2019-2020 | |
| Tersera Therapeutics LLC | $216.18 | 2019 | |
| Pfizer INC. | $207.13 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.43 | 2019 | |
| Horizon Therapeutics Plc | $92.98 | 2019 | |
| Boston Scientific Corporation | $89.57 | 2024-2025 | General - Pain Management |
| Takeda Pharmaceuticals U.S.A., INC. | $85.94 | 2019 | |
| Amgen INC. | $80.26 | 2019 | |
| Scilex Pharmaceuticals INC. | $73.84 | 2019-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $69.39 | 2019 | |
| Sentynl Therapeutics, INC. | $65.03 | 2019 | |
| Orexo US, INC. | $55.98 | 2019 | |
| Lilly USA, LLC | $53.19 | 2019 | |
| Mdd US Operations, LLC | $52.43 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Promius Pharma LLC | $42.69 | 2019 | |
| Averitas Pharma INC. | $38.83 | 2023-2024 | Qutenza |
| Biodelivery Sciences International, INC. | $35.98 | 2019-2021 | |
| Pacira Therapeutics, INC. | $30.69 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $25.00 | 2025 | Zilretta |
| Convatec INC. | $24.66 | 2024 | |
| Abbott Laboratories | $24.63 | 2019 | |
| Zyla Life Sciences, INC. | $22.77 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $21.07 | 2025 | |
| Nalu Medical, INC. | $19.89 | 2025 | Nalu Neurostimulation System |
| Daiichi Sankyo INC. | $14.80 | 2019 | |
| Stryker Corporation | $13.85 | 2022 | |
| Ibsa Pharma INC. | $13.41 | 2021 | |
| Stimwave Technologies Incorporated | $12.77 | 2021 | |
| Spr Therapeutics, INC | $12.55 | 2023 | Sprint Pns System |
| Assertio Therapeutics, INC. | $12.28 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.75 | 2019 | |
| Merck Sharp & Dohme LLC | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Overbey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.